1. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)
- Author
-
Raymond K. Cross, Jonathan P. Katz, David A. Schwartz, Seema Patil, Guruprasad Jambaulikar, Charlene C. Quinn, Patricia Langenberg, Leyla Ghazi, Mahrukh Riaz, Sandra M. Quezada, Dawn B. Beaulieu, Barathi Sivasailam, Katharine M. Russman, Sara N. Horst, Miguel Regueiro, Joseph F. Collins, and J. Kathleen Tracy
- Subjects
Adult ,Male ,medicine.medical_specialty ,Telemedicine ,Randomization ,MEDLINE ,Disease ,Inflammatory bowel disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Quality of life ,Randomized controlled trial ,law ,Internal medicine ,Health care ,medicine ,Humans ,Text Messaging ,Hepatology ,business.industry ,Gastroenterology ,Health Services ,Middle Aged ,Inflammatory Bowel Diseases ,medicine.disease ,digestive system diseases ,Telephone ,Hospitalization ,030220 oncology & carcinogenesis ,Quality of Life ,Colitis, Ulcerative ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1 year randomized trial of IBD patients receiving telemedicine versus standard care. Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in health care utilization among groups was a secondary aim. 348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 ± 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn’s disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control −5.2 ± 5.0 to 3.7 ± 3.6, TELE-IBD EOW 4.7 ± 4.1 to 4.2 ± 3.9, and TELE-IBD weekly 4.2 ± 4.2 to 3.2 ± 3.4, p
- Published
- 2018
- Full Text
- View/download PDF